YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia

Molecular and Cellular Endocrinology

Volumn 413, Issue , 2015, Pages 202-208

  Brownfoot, Fiona C ^a   Tong, Stephen ^a   Hannan, Natalie J ^a   Hastie, Roxanne ^a   Cannon, Ping ^a   Tuohey, Laura ^a   Kaitu'u Lino, Tu'uhevaha J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Endothelial dysfunction; HIF1 ; Hypertension; Oxidative stress; Preeclampsia; YC 1

Indexed keywords

ANGIOGENIC FACTOR; ENDOGLIN; GUANYLATE CYCLASE ACTIVATOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; 3-(5'-HYDROXYMETHYL-2'-FURYL)-1-BENZYLINDAZOLE; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; FLT1 PROTEIN, HUMAN; INDAZOLE DERIVATIVE; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOCYTE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TROPHOBLAST; UMBILICAL VEIN ENDOTHELIAL CELL; ADULT; BIOSYNTHESIS; METABOLISM; PATHOLOGY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY;

ADULT; ANTIGENS, CD; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDAZOLES; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84938291103     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.06.033     Document Type: Article

References (32)

1. ACOG Report of the american college of obstetricians and gynecologists' task force on hypertension in pregnancy. Obstet. Gynecol. 2013, 122:1122-1131.
2. Borzychowski A.M., Sargent I.L., Redman C.W. Inflammation and pre-eclampsia. Semin. Fetal Neonatal Med. 2006, 11:309-316.
3. Brownfoot F.C., Hannan N., Onda K., Tong S., Kaitu'u-Lino T. Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells. Placenta 2014, 35:724-731.
4. Caniggia I., Winter J.L. Adriana and Luisa Castellucci award lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies-a review. Placenta 2002, 23(Suppl. A):S47-S57.
5. Chaiworapongsa T., Chaemsaithong P., Yeo L., Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat. Rev. Nephrol. 2014, 10:466-480.
6. Chaiworapongsa T., Chaemsaithong P., Korzeniewski S.J., Yeo L., Romero R. Pre-eclampsia part 2: prediction, prevention and management. Nat. Rev. Nephrol. 2014, 10:531-540.
7. Galle J., Zabel U., Hubner U., Hatzelmann A., Wagner B., Wanner C., Schmidt H.H. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol. 1999, 127:195-203.
8. Granger J.P., LaMarca B.B., Cockrell K., Sedeek M., Balzi C., Chandler D., Bennett W. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol. Med. 2006, 122:383-392.
9. Jebbink J., Keijser R., Veenboer G., van der Post J., Ris-Stalpers C., Afink G. Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth. Hypertension 2011, 58:70-76.
10. Kaitu'u-Lino T.J., Palmer K.R., Whitehead C.L., Williams E., Lappas M., Tong S. MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. Am. J. Pathol. 2012, 180:888-894.
11. Karumanchi S.A., Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology 2004, 145:4835-4837.
12. Lunell N.O., Lewander R., Mamoun I., Nylund L., Sarby S., Thornstrom S. Uteroplacental blood flow in pregnancy induced hypertension. Scand. J. Clin. Lab. Invest. Suppl. 1984, 169:28-35.
13. Maynard S., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., Libermann T.A., Morgan J.P., Sellke F.W., Stillman I.E., Epstein F.H., Sukhatme V.P., Ananth Karumanchi S. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in pre-eclampsia. J. Clin. Invest. 2003, 111:649-658.
14. Nishikawa S., Miyamoto A., Yamamoto H., Ohshika H., Kudo R. The relationship between serum nitrate and endothelin-1 concentrations in preeclampsia. Life Sci. 2000, 67:1447-1454.
15. Rajakumar A., Brandon H.M., Daftary A., Ness R., Conrad K.P. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004, 25:763-769.
16. Ramos-Espiritu L.S., Hess K.C., Buck J., Levin L.R. The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells. J. Pharmacol. Exp. Ther. 2011, 338:925-931.
17. Rana S., Rajakumar A., Geahchan C., Salahuddin S., Cerdeira A.S., Burke S.D., George E.M., Granger J.P., Karumanchi S.A. Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1alpha pathway. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2014, 28(10).
18. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594.
19. Sanchez-Aranguren L.C., Prada C.E., Riano-Medina C.E., Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front. Physiol. 2014, 5:372.
20. Sanchez-Elsner T., Botella L.M., Velasco B., Langa C., Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 2002, 277:43799-43808.
21. Sibai B.M., Caritis S., Hauth J. What we have learned about preeclampsia. Semin. Perinatol. 2003, 27:239-246.
22. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365:785-799.
23. Stasch J.P., Evgenov O.V. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb. Exp. Pharmacol. 2013, 218:279-313.
24. Stasch J.P., Pacher P., Evgenov O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011, 123:2263-2273.
25. Tal R., Shaish A., Barshack I., Polak-Charcon S., Afek A., Volkov A., Feldman B., Avivi C., Harats D. Am. J. Pathol. 2010, 177(6). ajpath.2010.090800.
26. Tu'uhevaha J., Kaitu'u-Lino S.T., Beard Sally, Hastie Roxanne, Tuohey Laura, Brownfoot Fiona, Onda Kenji, Hannan Natalie J. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin. Pregnancy Hypertens. 2014, 4:287-295.
27. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., Bdolah Y., Lim K.H., Yuan H.T., Libermann T.A., Stillman I.E., Roberts D., D'Amore P.A., Epstein F.H., Sellke F.W., Romero R., Sukhatme V.P., Letarte M., Karumanchi S.A. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006, 12:642-649.
28. Whitehead C.L., Palmer K.R., Nilsson U., Gao Y., Saglam B., Lappas M., Tong S. Placental expression of a novel primate-specific splice variant of sFlt-1 is upregulated in pregnancies complicated by severe early onset pre-eclampsia. BJOG: Int. J. Obstet. Gynaecol. 2011, 118:1268-1271.
29. Wohlfart P., Malinski T., Ruetten H., Schindler U., Linz W., Schoenafinger K., Strobel H., Wiemer G. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br. J. Pharmacol. 1999, 128:1316-1322.
30. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., Park J.W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 2003, 95:516-525.
31. Yoshida T., Zhang H., Iwase T., Shen J., Semenza G.L., Campochiaro P.A. Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2010, 24:1759-1767.
32. Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., Rey S., Hammers H., Chang D., Pili R., Dang C.V., Liu J.O., Semenza G.L. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19579-19586.